Search Within

Michel W J Sadelain

Formats
  1. Meeting Abstract (289)
  2. Journal Article (279)
  3. Review (5)
  4. Editorial (4)
  5. Conference Paper (3)
  6. Research Letter (3)
  7. Book Section (2)
Groups
  1. Center for Hematologic Malignancies (585)
  2. Department of Medicine (585)
  3. GSK Faculty (585)
  4. Hematologic Malignancies Research (585)
  5. Hematologic Malignancies, Division of (585)
  6. Molecular Pharmacology and Chemistry Program Faculty (585)

More Groups

People
  1. Isabelle Riviere (200)
  2. Renier Brentjens (116)
  3. Xiuyan Wang (91)
  4. Jae Park (83)
  5. Jorge Mansilla-Soto (43)
  6. Kevin Curran (36)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (21)
  4. 2022 (18)
  5. 2021 (23)
  6. 2020 (16)

More Years

Publications
  1. Blood (133)
  2. Molecular Therapy (56)
  3. Cancer Research (24)
  4. Journal of Clinical Oncology (18)
  5. Nature Biotechnology (13)
  6. Blood Cells, Molecules, and Diseases (12)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. Nature Publishing Group (126)
  3. Elsevier Inc. (49)
  4. American Association for Cancer Research (46)
  5. American Society of Clinical Oncology (19)
  6. Cell Press (16)

More Publishers

Results (585)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAR therapy - The CD19 paradigm
    Meeting Abstract

    Sadelain, M.
    The Oncologist (2015)

    Fulltext@MSK | Save
  • The quest for spatio-temporal control of CAR T cells
    Journal Article

    Sun, J.; Sadelain, M.
    Cell Research (2015)

    Fulltext@MSK | Save
  • Comparison of CTS™ Dynabeads® CD3/CD28, Miltenyi TransAct CD3/28 and ExpAct Beads for large-scale CAR T cell manufacturing
    Meeting Abstract

    Wang, X.; Stefanski, J.; Borquez-Ojeda, O.; Qu, J.; Hack, A.; He, Q.; Wasielewska, T.; Du, F.; Sadelain, M.; Riviere, I.
    Human Gene Therapy (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R.
    Haematologica (2015)

    Fulltext@MSK | Save
  • CAR therapy: The CD19 paradigm
    Journal Article

    Sadelain, M.
    Journal of Clinical Investigation (2015)

    Fulltext@MSK | Save
  • Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells
    Journal Article

    Zhao, Z.; Condomines, M.; Van Der Stegen, S. J. C.; Perna, F.; Kloss, C. C.; Gunset, G.; Plotkin, J.; Sadelain, M.
    Cancer Cell (2015)

    Fulltext@MSK | Save
  • Phase I clinical trial of autologous CD19-targeted 19-28z CAR T cells in adult patients with Relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Halton, E.; Quintanilla, H.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R. J.
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Repair of the sickle-cell disease mutation in human stem cells using CRISPR/Cas9 and single-stranded oligodeoxynucleotides
    Meeting Abstract

    Mansilla-Soto, J.; Leyfman, Y.; Sadelain, M.
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Activation signals from CD19-CAR permit NFAT-controlled inducible expression of transgenes in PBMCs
    Meeting Abstract

    Uchibori, R.; Teruya, T.; Ninomiya, S.; Ido, H.; Tsukahara, T.; Ohmine, K.; Urabe, M.; Saga, Y.; Kume, A.; Mizukami, H.; more...
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Optimal activation of both CD28 and 4-1BB in CAR-targeted T cells results in enhanced tumor eradication
    Meeting Abstract

    Zhao, Z.; Van Der Stegen, S. J. C.; Condomines, M.; Perna, F.; Gunset, G.; Plotkin, J.; Sadelain, M.
    Molecular Therapy (2015)

    Fulltext@MSK | Save